Posted by Michael Wonder on 08 May 2025
European Commission approves Tremfya (guselkumab), the first dual-acting IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's disease
7 May 2025 - Data from the pooled GALAXI 2 and 3 studies showed that guselkumab demonstrated greater efficacy compared to ustekinumab in endoscopic response and endoscopic remission both at Week 48, including the biologic naïve and prior biologic failure subgroups.
Johnson & Johnson today announced that the European Commission has approved a marketing authorisation for Tremfya (guselkumab), the first dual-acting IL -23 inhibitor offering both intravenous and subcutaneous induction options, for the treatment of adults with moderately to severely active Crohn's disease and who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biological treatment.
